文献速递急性肾损伤

不同抗病毒药物与成人带状疱疹住院获得性急性肾损伤的关联

Associations between Different Antivirals and Hospital-Acquired Acute Kidney Injury in Adults with Herpes Zoster.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-03-26

基于中国肾脏数据系统3273例因带状疱疹住院并接受抗病毒治疗的成人患者,采用KDIGO标准判定并分期住院获得性AKI,用Cox比例风险模型比较不同抗病毒药物的相对风险。结果显示,静脉抗病毒药物中阿昔洛韦的住院获得性AKI风险最高,其次为喷昔洛韦/更昔洛韦和膦甲酸钠,且静脉核苷类似物的风险呈剂量依赖性。

要点

  • 静脉抗病毒药物中,阿昔洛韦的住院获得性AKI风险最高。
  • 与阿昔洛韦/伐昔洛韦相比,喷昔洛韦/泛昔洛韦/更昔洛韦和膦甲酸钠的AKI风险更低。
  • 静脉核苷类似物的住院获得性AKI风险呈剂量依赖性。

核心结论

  • 在带状疱疹抗病毒治疗中,不同抗病毒药物(尤其是静脉给药)的住院获得性AKI风险不同。
  • 静脉抗病毒药物中,阿昔洛韦的住院获得性AKI风险最高,其次为喷昔洛韦/更昔洛韦和膦甲酸钠。

研究设计与样本

  • 研究从中国肾脏数据系统选取3273例住院期间接受抗病毒治疗的成人带状疱疹患者。
  • 采用患者水平血清肌酐数据,按KDIGO标准判定并分期AKI。
  • 使用Cox比例风险模型比较不同抗病毒药物组住院获得性AKI的相对风险。

主要发现

  • 3273例患者中,1480例(45%)使用阿昔洛韦/伐昔洛韦,681例(21%)使用更昔洛韦,489例(15%)使用喷昔洛韦/泛昔洛韦,623例(19%)使用膦甲酸钠。
  • 随访期间共发生111例住院获得性AKI,主要为AKI 1期。
  • 阿昔洛韦/伐昔洛韦、更昔洛韦、喷昔洛韦/泛昔洛韦和膦甲酸钠组的住院获得性AKI累积发生率分别为5%、3%、3%和1%。
  • 与阿昔洛韦/伐昔洛韦相比,喷昔洛韦/泛昔洛韦/更昔洛韦和膦甲酸钠的调整风险比分别为0.59(95%CI 0.37至0.94)和0.27(95%CI 0.11至0.63)。
  • 与静脉阿昔洛韦相比,静脉喷昔洛韦/更昔洛韦和膦甲酸钠的调整风险比分别为0.53(95%CI 0.29至0.98)和0.31(95%CI 0.12至0.76)。

关键数值与推荐

  • 住院获得性AKI按KDIGO标准基于血清肌酐判定并分期。
  • 与阿昔洛韦/伐昔洛韦相比,喷昔洛韦/泛昔洛韦/更昔洛韦的调整HR为0.59(95%CI 0.37至0.94),膦甲酸钠为0.27(95%CI 0.11至0.63)。
  • 与静脉阿昔洛韦相比,静脉喷昔洛韦/更昔洛韦的调整HR为0.53(95%CI 0.29至0.98),膦甲酸钠为0.31(95%CI 0.12至0.76)。

临床怎么用

  • 对带状疱疹住院成人选择抗病毒药物时,应评估住院获得性AKI风险,尤其是静脉用药。
  • 静脉阿昔洛韦与最高的住院获得性AKI风险相关,考虑替代药物时需结合病情个体化决策。
  • 使用静脉核苷类似物时,风险呈剂量依赖性,需关注剂量相关肾毒性监测。

局限性

  • 结论需在其他人群的大样本研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Among intravenous antivirals, acyclovir was associated with the highest risk of hospital-acquired AKI, followed by penciclovir/ganciclovir and foscarnet. The risk of hospital-acquired AKI was dose dependent for intravenous nucleoside analogs. BACKGROUND: To examine the association of use of different antivirals with hospital-acquired AKI among Chinese adults with herpes zoster. METHODS: This study selected 3273 adult patients who received antiviral therapy for herpes zoster during hospitalization from the China Renal Data System. We identified and staged AKI using patient-level serum creatinine data according to the Kidney Disease Improving Global Outcomes criteria. We compared the relative risks of hospital-acquired AKI among patients treated with different antivirals using Cox proportional hazards models. RESULTS: Among 3273 patients, 1480 (45%), 681 (21%), 489 (15%), and 623 (19%) were treated with acyclovir/valacyclovir, ganciclovir, penciclovir/famciclovir, and foscarnet, respectively. During the follow-up period, a total of 111 cases of hospital-acquired AKI occurred, predominantly classified as AKI stage 1. The cumulative incidences of hospital-acquired AKI were 5%, 3%, 3%, and 1% in the patients receiving acyclovir/valacyclovir, ganciclovir, penciclovir/famciclovir, and foscarnet, respectively. Compared with acyclovir/valacyclovir, penciclovir/famciclovir/ganciclovir and foscarnet were associated with a lower risk of hospital-acquired AKI, with an adjusted hazard ratio of 0.59 (95% confidence interval [CI], 0.37 to 0.94) and 0.27 (95% CI, 0.11 to 0.63), respectively. Compared with intravenous acyclovir, intravenous penciclovir/ganciclovir and foscarnet were associated with a lower risk of hospital-acquired AKI with an adjusted hazard ratio of 0.53 (95% CI, 0.29 to 0.98) and 0.31 (95% CI, 0.12 to 0.76), respectively. The associations were consistent across various subgroups and sensitivity analyses. CONCLUSIONS: Among antiviral therapies for herpes zoster, we found different risks of hospital-acquired AKI among the patients receiving different antivirals, in particular, those administered intravenously. Among intravenous antivirals, acyclovir was associated with the highest risk of hospital-acquired AKI, followed by penciclovir/ganciclovir and foscarnet. Confirmation studies with large samples from other populations are warranted.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Xu R, Gao Q, Zhang Y, et al. Associations between Different Antivirals and Hospital-Acquired Acute Kidney Injury in Adults with Herpes Zoster. Clin J Am Soc Nephrol. 2024. PMID: 38527975. doi:10.2215/CJN.0000000000000452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。